Pristinamycin

Pristinamycin, synthesized by Streptomyces pristinaespiralis, is an orally administered antibiotic resembling streptogramin, comprising two distinct components: Pristinamycin I (PI) and Pristinamycin II (PII). This compound exhibits a high efficacy against various antibiotic-resistant pathogens, especially Gram-positive bacteria such as Methicillin-resistant Staphylococcus aureus (MRSA), Vancomycin-resistant S. aureus (VRSA), and Enterococcus faecium (VREF) [1].

Pristinamycin IA (Mikamycin B) is a cyclo-peptidic macrolactone antibiotic and a substrate for the P-glycoprotein.

Pristinamycin IB (Ostreogrycin B2) is a lipopetide antibiotic effective against Gram-positive bacteria.

Pristinamycin IIB is a streptolysin antibiotic that exhibits activity against Gram-positive bacteria.

Pristinamycin IC is an ester peptide antibiotic with activity against Gram-positive bacteria.

Virginiamycin M1 (Pristinamycin IIA) is a macrocyclic lactone peptide antibiotic and is a member of the streptogramin A group of antibiotics.